Abstract: Multiplexed immunoassays are performed using cells expressing on their surface capture agents such as antibodies or antibody fragments. The cells serve as the solid phase supporting the capture agent and also express identifiers encoding the nature of the capture agent, allowing the cells to be used in multiplexed assays. For example, the identifiers can be internally expressed fluorescent proteins or externally expressed proteins that bind to tagged antibody reagents. Analyte detection and quantification are performed by detection antibodies binding to bound analyte or by detection proteins expressed by the cell in response to analyte binding. By encoding capture, identification, and analyte detection functionalities within the cell, expensive and time-consuming steps of antibody preparation, purification, and coupling to a solid phase are eliminated, making the cells advantageous over antibody-coupled beads currently used in multiplexed immunoassays.

Abstract: A random peptide library constructed by transforming host cells with a collection of recombinant vectors that encode a fusion protein comprised of a DNA binding protein and a random peptide and also encode a binding site for the DNA. binding protein can be used to screen for novel ligands. The screening method results in the formation of a complex comprising the fusion protein bound to a receptor through the random peptide ligand and to the recombinant DNA vector through the DNA binding protein.

Abstract: The present invention is directed to a process for amplifying and detecting any target nucleic acid sequence contained in a nucleic acid or mixture thereof and for assembling large polynucleotides from component polynucleotides, each involving generating concatemers formed by PCR amplification of overlapping fragments.

Abstract: A random peptide library constructed by transforming host cells with a collection of recombinant vectors that encode a fusion protein comprised of a DNA binding protein and a random peptide and also encode a binding site for the DNA binding protein can be used to screen for novel ligands. The screening method results in the formation of a complex comprising the fusion protein bound to a receptor through the random peptide ligand and to the recombinant DNA vector through the DNA binding protein.